In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Erasca's net current asset value per share for the quarter that ended in Dec. 2024 was $0.81.
The historical rank and industry rank for Erasca's Net Current Asset Value or its related term are showing as below:
ERAS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.33 Med: 2.49 Max: 4.95
Current: 1.46
During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Erasca was 4.95. The lowest was 1.33. And the median was 2.49.
ERAS's Price-to-Net-Current-Asset-Value is ranked better than 73.32% of 997
companies
in the Biotechnology industry
Industry Median: 3.29
vs ERAS: 1.46
Erasca Net Current Asset Value Historical Data
The historical data trend for Erasca's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Erasca's Net Current Asset Value
For the Biotechnology subindustry, Erasca's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Erasca's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Erasca's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca (NAS:ERAS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Erasca Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of Erasca's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERAS has been successfully added to your 